MedPath

Efficacy of Artificial Intelligence for Gatekeeping in Referrals to Specialized Care

Not Applicable
Not yet recruiting
Conditions
Primary Care
Primary Care Patients With Chronic Conditions
Registration Number
NCT07019116
Lead Sponsor
Hospital de Clinicas de Porto Alegre
Brief Summary

In Rio Grande do Sul, Brazil, the demand for specialty care referrals has increased sharply with the adoption of the electronic regulatory system, especially in rural areas. In 2023 alone, over 79,000 referrals were submitted monthly, totaling 1.7 million annual gatekeeping decisions. Due to workforce limitations, nearly 70% of referrals are authorized automatically, often without clinical validation. This leads to delays for high-risk patients, unnecessary specialist visits, and a growing backlog, currently over 172,000 pending referrals. To address this, an AI algorithm was developed to triage referrals based on urgency and appropriateness.

The investigators propose a prospective controlled study with randomized implementation of the AI tool across selected specialty queues in the electronic referral system. The population will consist of referrals from specialties waitlists from municipalities in Rio Grande do Sul. Specialties to be included will be selected by the State Health Department prospectively according to gatekeeping needs. The intervention will be an AI-based triage algorithm. The control will be a standard gatekeeping process. The primary outcome is the proportion of referrals with a final decision (authorized or redirected to primary care) within six months; secondary outcomes include time to decision and appointment, system-level performance metrics. Referrals will be randomly assigned to algorithmic or human gatekeeping with a 1:1 ratio. The algorithm classifies referrals into two groups: not authorized (pending more data or teleconsultation), authorized. Authorization cases are further divided into routine and high-risk referrals to help the manage demand. Each AI prediction provides a probability from 0 to 1 of authorization (or deferring). The implementation threshold is set at 0.8; cases below this level will be classified as low confidence for decision and will not be included. According to the State Health Department's decisions, several referral lines are expected to be selected for the intervention. A sample size 934 (467 per arm) for each included specialty was calculated to detect a 1.2 relative risk for the primary outcome with 90% power and 5% significance.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
934
Inclusion Criteria
  • All referrals from a given specialty (waitlist) will be eligible.
  • Specialties will be selected following Rio Grande do Sul Health Department priorities.
Exclusion Criteria
  • Referrals that the AI algorithm can not evaluate. These include referrals with attachments (further information in image or PDF files) and referrals with previous rounds of discussion.
  • Referrals in which the algorithm has low confidence in the decision (i.e., informed data lead to a decision with a probability below 80%) will not be included in the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Referrals with final decision6 months

The proportion of referrals with a final decision includes those authorized for specialist care and those redirected to primary care without an in-person specialist consultation.

Secondary Outcome Measures
NameTimeMethod
Time to final decision6 months

Time to final decision (authorization or deferral) for the referral.

Waitlist size over time6 months

The overall size of the referral waitlist will be assessed before and after the implementation of the algorithm.

Time to consult in high-risk patients6 months

Time to specialist appointment for high-priority (red/orange) cases.

Use of remote consultations6 months

Rio Grande do Sul has a provider-to-provider consultation service. The proportion of referrals that used this service will be assessed.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.